# Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

Study · id `cardio:ct-nct03015909` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03015909](<https://clinicaltrials.gov/study/NCT03015909>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03015909

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

## Technical summary

Registry record NCT03015909. Allocation not applicable; no masking; primary purpose treatment. Start 2016-08-11 (actual); primary completion 2017-12-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 116 participants (enrolled count; ClinicalTrials.gov record NCT03015909, source copy `cardio:ctgov-nct03015909-2019-01-03`, retrieved 2026-10-26)
- Started: 2016-08-11 (actual) (ClinicalTrials.gov record NCT03015909, source copy `cardio:ctgov-nct03015909-2019-01-03`, retrieved 2026-10-26)
- Primary completion: 2017-12-21 (actual) (ClinicalTrials.gov record NCT03015909, source copy `cardio:ctgov-nct03015909-2019-01-03`, retrieved 2026-10-26)
- Completion: 2017-12-21 (actual) (ClinicalTrials.gov record NCT03015909, source copy `cardio:ctgov-nct03015909-2019-01-03`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03015909, source copy `cardio:ctgov-nct03015909-2019-01-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03015909-2019-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
- Condition: Short Stature, Idiopathic
- Condition: Infant, Small for Gestational Age
- Condition: Growth Hormone Deficiency
- Condition: Chronic Renal Failure
- Condition: Turner Syndrome
- Intervention (Drug): Somatropin
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: 97bcf8907ff7a1ff6e710f474bf585a151ef9a3168fc788ec56517ed8728b543
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
